Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

Abstract

Docetaxel at this dose and schedule has a high level of antitumor activity in patients with treatment-refractory advanced breast cancer, and appears to be one of the most active agents for the treatment of this patient population.